CRT 2026 | TAVI-CLOSE Trial: Dual Suture vs Suture + Plug for Vascular Closure After Transfemoral TAVI

The transfemoral approach is the predominant strategy for transcatheter aortic valve implantation (TAVI). Although vascular complications are currently less frequent, they remain relevant determinants of procedural success.

The TAVI-CLOSE study evaluated the efficacy and safety of two femoral access closure strategies after TAVI: closure with a dual suture device (dual Perclose ProGlide) vs a hybrid strategy consisting of a single suture plus a vascular plug (Perclose + Angio-Seal).

This was a prospective, randomized, single-center study conducted in the United States, in which patients were assigned in a 1:1 ratio to one of the two vascular closure strategies. Clinical follow-up extended to 30 days.

The primary endpoint (PE) was a composite of major access-site related bleeding and major vascular complications according to VARC-3 definitions. Secondary endpoints included minor vascular complications and total hospitalization costs.

The incidence of the primary endpoint was 2.1% in the dual suture group vs 7.1% in the suture + plug group. The absolute risk difference was 5% (95% CI −3.8% to 13.8%), exceeding the predefined non-inferiority margin.

Read also: CRT 2026 | CUT-DRESS Trial: Lesion Preparation with Cutting Balloon.

No serious events such as death, limb ischemia, embolization, or vascular perforation were reported. Procedural duration, fluoroscopy time, contrast volume, and length of hospital stay (approximately 1.1 days in both groups) were similar between strategies. Likewise, no differences were observed in total hospitalization costs, with a mean cost of approximately $42,000.

TAVI-CLOSE is the first randomized study conducted in the United States comparing vascular closure strategies after TAVI. The study demonstrated a low overall complication rate, with dual suture device closure emerging as the reference strategy.

Presented by Imran Baig at Late Breaking Clinical Trials, CRT 2026, Washington, USA.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Omar Tupayachi
Dr. Omar Tupayachi
Member of the Editorial Board of solaci.org

More articles by this author

CRT 2026 | NAVITOR IDE: Hemodynamic Outcomes and 5-Year Durability of an Intra-Annular Self-Expanding Transcatheter Aortic Valve

As TAVI expands into younger populations and patients with lower surgical risk, prosthesis durability has become a key aspect of long-term management. The NAVITOR...

One-Year Results of ENCIRCLE: Percutaneous Mitral Valve Replacement in Patients Ineligible for Surgery or TEER

Symptomatic mitral regurgitation (MR) in patients who are not candidates for surgery or transcatheter edge-to-edge repair (TEER) remains a highly complex clinical scenario associated...

Can Coronary CT Angiography Replace Invasive Coronary Angiography in Pre-TAVI Coronary Assessment?

Coronary artery disease coexists in approximately half of patients undergoing transcatheter aortic valve implantation, making coronary assessment prior to the procedure essential. Invasive coronary...

Valve-in-Valve in Small Surgical Aortic Bioprostheses: Balloon-Expandable or Self-Expanding? Three-Year Results from the LYTEN Trial

Dysfunction of small surgical aortic bioprostheses represents a challenging scenario for transcatheter aortic valve replacement in the valve-in-valve setting, due to the higher incidence...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

CRT 2026 | NAVITOR IDE: Hemodynamic Outcomes and 5-Year Durability of an Intra-Annular Self-Expanding Transcatheter Aortic Valve

As TAVI expands into younger populations and patients with lower surgical risk, prosthesis durability has become a key aspect of long-term management. The NAVITOR...

CRT 2026 | CUT-DRESS Trial: Lesion Preparation with Cutting Balloon

In-stent restenosis (ISR) continues to represent a relevant clinical challenge in contemporary coronary angioplasty practice. Despite advances in drug-eluting stents, neointimal hyperplasia and suboptimal...

CRT 2026 | Clopidogrel vs Aspirin as Long-Term Monotherapy After Coronary Angioplasty

The use of aspirin as chronic antiplatelet therapy after percutaneous coronary intervention (PCI) has historically been the standard recommended by international guidelines. However, recent...